Aripiprazole Orally Disintegrating Tablets
The efficacy of aripiprazole against schizophrenia has been established in short-term (4-week and 6-week) controlled studies involving schizophrenia patients. Physicians who choose aripiprazole for long-term treatment should regularly re-evaluate its long-term efficacy in individual patients.
Product Category：
Product Description
[Product Name] Aripiprazole
[Generic Name] Aripiprazole Orally Disintegrating Tablets
[Approval No.] 10 mg: GYZZ H20213355
[Specification] YBH01272021
[Dosage and Administration] The recommended initial and therapeutic doses are 10 or 15 mg/day. The maximum daily dose should be ≤30 mg.
[Indications] Schizophrenia. The efficacy of aripiprazole against schizophrenia has been established in short-term (4-week and 6-week) controlled studies involving schizophrenia patients. Physicians who choose aripiprazole for long-term treatment should regularly re-evaluate its long-term efficacy in individual patients.
[Strength] 10mg
[Storage] Store in airtight containers.
[Packaging] 10 mg*28 tablets/carton.
[Manufacturer] Sunshine Lake Pharma Co., Ltd.
[China General Distributor] Shenzhen Foncoo Pharmaceutical Co., Ltd.
ONLINE MESSAGE
*Note: Please be sure to fill in the information accurately and keep the communication open, we will get in touch with you as soon as possible
Related Products
Contact Us：
Room 1502-1506, Building D2, Nanshan iPark, No. 1001, Xueyuan Avenue, Changyuan Community, Taoyuan Street, Nanshan District, Shenzhen, China.
Follow Us
© COPYRIGHT 2021 Shenzhen Foncoo Pharmaceutical Co., Ltd. ALL RIGHTS RESERVED